The
Report PharmaPoint: Psoriasis - Global Drug Forecast and Market
Analysis to 2024 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Psoriasis (PsO) is an incurable
genetic, systemic, inflammatory, and chronic skin disorder with an
overall prevalence of 2-3% worldwide. Specifically, adult plaque
psoriasis, the most common form of Psoriasis, is the focus of this
report. Although not life-threatening, Psoriasis causes tremendous
morbidity and personal angst for patients.
GlobalData projects the
psoriasis market in 8MM to experience modest growth during the
forecast period at a CAGR of 7.26%. This growth will be driven
primarily by the highly anticipated arrivals of promising systemic
therapies- interleukin-23 (IL-23) inhibitors (guselkumab and
tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz,
and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla
(apremilast). Nevertheless, looming patent expiries of high-grossing
branded drugs- especially TNF inhibitors, Humira, Enbrel and
Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and
Japan, along with rapid global developments of biosimilars , are
expected to spread the growth throughout the different classes of
products, away from the branded TNF inhibitors which have
traditionally been the main driver of growth in the prior years.
View Report At
:http://www.marketresearchreports.biz/analysis/754850
Highlights
Key Questions Answered
- How good is the management of
Psoriasis with marketed therapies?
- Which drugs and players are
important in the current management landscape?
- What are the most promising
late-stage pipeline drugs and how will their launch shape the future
treatment landscape in the Psoriasis market?
- What are the significant
unmet needs and remaining opportunities in the Psoriasis market?
- What clinical and commercial
factors are likely to uptake of Psoriasis therapies in the US, 5EU,
Japan and India?
Key Findings
- The psoriasis market is
currently very dynamic, with effective biologic therapies awaiting
approval, such as interleukin-17 (IL-17) inhibitor- brodalumab,
interleukin-23 (IL-23) inhibitors- guselkumab and tildrakizumab.
- Novel biologic therapies will
challenge the current anti-TNF biologics in an attempt to dislodge
their stronghold, if their safety and efficacy profiles are proven
once they enter the market.
- The impending patent cliff
for biologics will allow for the emergence of biosimilars to all the
marketed biologic brands. Patent expiries take place during the
forecast period for the current market leaders such as Johnson &
Johnsons Remicade (infliximab), AbbVies Humira (adalimumab), Amgens
Enbrel (etanercept) and Johnson & Johnsons Stelara (ustekinumab).
- The drivers for market growth
will also include affordable treatments throughout the world, as well
as the push for long-term drug efficacy. The main challenge for
individual drugs will be to distinguish themselves in a crowded
marketplace, comprising a highly diversified field of therapies, with
existing drugs struggling to increase their patient share.
Scope
- Overview of Psoriasis,
including epidemiology, etiology, pathophysiology, symptoms and
current treatment options
- Topline Psoriasis market
revenue from 2014-2024. Annual cost of therapy (ACOT) and major
pipeline product sales in this forecast period are included.
- Key topics covered include
strategic competitor assessment, unmet needs, pipeline assessment,
and market outlook for the Psoriasis market.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, synopses of innovative early-stage
projects, and detailed analysis of late-stage pipeline products-
including promising IL-17 and IL-23 inhibitors.
- Analysis of the current and
future market competition in the global Psoriasis market (8MM).
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies
by understanding the trends shaping and driving the global Psoriasis
market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the Psoriasis market
in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/754850
Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and
Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 25
3.2 Symptoms 28
4 Epidemiology 30
4.1 Disease Background 30
4.2 Risk Factors and
Comorbidities 30
4.3 Global Trends 31
4.3.1 Prevalence 31
4.4 Forecast Methodology 33
4.4.1 Sources Used for One-Year
Diagnosed Prevalence of Psoriasis 35
4.4.2 Sources Not Used 37
4.4.3 Forecast Assumptions and
Methods, One-Year Diagnosed Prevalent Cases of Psoriasis 38
4.5 Epidemiological Forecast
for Psoriasis (2014-2024) 40
4.5.1 One-Year Diagnosed
Prevalent Cases of Psoriasis 40
4.5.2 Age-Specific One-Year
Diagnosed Prevalent Cases of Psoriasis 42
4.5.3 Sex-Specific One-Year
Diagnosed Prevalent Cases of Psoriasis 44
4.5.4 Age-Standardized One-Year
Diagnosed Prevalent Cases of Psoriasis 46
4.5.5 One-Year Diagnosed
Prevalent Cases of Psoriasis by Severity 47
4.6 Discussion 48
4.6.1 Epidemiological Forecast
Insight 48
4.6.2 Limitations of the
Analysis 49
4.6.3 Strengths of the Analysis
49
5 Disease Management 50
5.1 Diagnosis and Treatment
Overview 50
5.1.1 Diagnosis 50
5.1.2 Leading Prescribed Drugs
and Treatment Guidelines 51
5.1.3 Clinical Practice 54
5.2 US 54
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment